Brief: RVL Pharmaceuticals reports Q2 results

RVL Pharmaceuticals

11/08/2022 11:54

Aug 11 (Reuters) - RVL Pharmaceuticals PLC  RVLP.O :
    * REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS; PROVIDES
COMMERCIAL UPDATE
    * Q2 2022 UPNEEQ® NET PRODUCT SALES OF $8.4 MILLION; 42%
ABOVE Q1
    * OPPORTUNITY FOR CASH RUNWAY TO EXTEND THROUGH 2023
FOLLOWING
RECENTLY ANNOUNCED FINANCINGS
    * AT JUNE 30, 2022, CASH AND CASH EQUIVALENTS WERE $27.4
MILLION
    * QTRLY LOSS PER ORDINARY SHARE BASIC AND DILUTED,
CONTINUING
OPERATIONS $0.14
    * Q2 EARNINGS PER SHARE VIEW $-0.21, REVENUE VIEW $8.5
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX8mmLTx 
Further company coverage:  RVLP.O